In cardiomyocytes, Ro 31-8220 decreased PKC-α expression and activity compared with cardiomyocytes cultured in high glucose. In cells, treatment produced significant redistribution of COPI coatomer staining as early as 5 min after treatment. In KB Telo MyoD cells (DM1), treatment resulted in a 91% reduction in CELF1 protein compared with DMSO. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
PKC-α expression and activity in cardiomyocytes
Cell-based study · cardiomyocytes; n = 4 or 5 [1]
Cardiomyocytes were treated with Ro 31-8220 at 50 nmol/L for 48 hours. Compared with cardiomyocytes cultured in high glucose, treatment decreased PKC-α expression and activity.
Literature-Reported Treatment Conditions
- Treatment concentration
- 50 nmol/L
- Exposure duration
- 48 hours
- Method
- adding PKC inhibitor Ro-31-8220
- Co-treatment
- Other interventions in this design: glucose 25.5 mmol/L; 5-Bru 0.1 mmol/L. Compound effect isolated by the comparison: compared with the cardiomyocytes cultured in high glucose levels.
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Ro 31-8220
The paper names Ro 31-8220 without stating the salt or form; not verified as the mesylate form supplied as A13514. No dose conversion or lot validation.
Methods > 2. Methods > 2.1 Culture of neonatal rat ventricular myocytes (S11); Results > 3.3 Effect of high glucose and PKC inhibitor Ro-31-8220 on the expression and activity of PKC in cardiomyocytes (S35, S36, S38); Figure 1 legend (S57, S59)
the expression and activity of PKC-α: the expression and activity of PKC-α; comparator: high glucose (25.5 mmol/L) — Figure 1 legend (S57)
COPI coatomer staining redistribution in cells
Cell-based study · cells [2]
Cells were treated with the compound at 5 μM, with vehicle-treated cells as the control. Significant redistribution of COPI coatomer staining occurred as early as 5 min after treatment.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5 μM
- Exposure duration
- over the indicated times
- Reported limits
- Not stated in the sentences used: route, vehicle.
Methods and source locations
Compound reported in the paper: Ro 31-8220
The paper names Ro 31-8220 without stating the salt or form; not verified as the mesylate form supplied as A13514. No dose conversion or lot validation.
Results > ERK8 regulates COPI-dependent GalNAc-Ts traffic (S119); Figure 5—figure supplement 1. legend (S348, S349, S353)
Quantification of the relative numbers of COPI transport carriers using the granularity measurement module in MetaXpress software: Quantification of the relative numbers of COPI transport carriers using the granularity measurement module in MetaXpress software; comparator: vehicle treated — Results > ERK8 regulates COPI-dependent GalNAc-Ts traffic (S119); Figure 5—figure supplement 1. legend (S349)
CELF1 protein reduction in KB Telo MyoD cells
Cell-based study · KB Telo MyoD cells (DM1) [3]
KB Telo MyoD cells (DM1) were treated with Ro 31-8220 at 10 μm. Compared with DMSO, treatment resulted in a 91% reduction in CELF1 protein normalized against α-tubulin levels.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 μm
- Co-treatment
- Other interventions in this design: an engineered lentivirus. Compound effect isolated by the comparison: DMSO.
- Reported limits
- Not stated in the sentences used: route, schedule, vehicle.
Methods and source locations
Compound reported in the paper: Ro 31-8220
The paper names Ro 31-8220 without stating the salt or form; not verified as the mesylate form supplied as A13514. No dose conversion or lot validation.
RESULTS > Primary screen for compounds that remove nuclear foci (S3); RESULTS > The effect of compounds on foci is not mediated by PKC (S124, S132, S133)
quantification of CELF1 protein normalized against α-tubulin levels: quantification of CELF1 protein normalized against α-tubulin levels; comparator: DMSO — RESULTS > The effect of compounds on foci is not mediated by PKC (S124, S133)